Scientific Programme 2026

The 34th Annual Meeting Scientific Committee established an inspiring programme* on the topic "Treatment Efficacy & Risk Management across the disease course".

* Changes to the programme may apply.

Hour Location	Title	Location
8:30 - 13:00 Room Carl 1&2	PROMS_Plenary session	Room Carl 1&2
13:00 - 14:00 Lobby	Lunch Break	Lobby
14:00 - 20:00 Room Carl 1&2	Advanced Curriculum for Multiple Sclerosis	Room Carl 1&2

Hour Location	Title	Location
11:30 - 12:30 Room Carl 1&2	Satellite Symposium	Room Carl 1&2
12:30 - 13:30 Lobby & Winter Garden	Light Lunch & Poster Viewing	Lobby & Winter Garden
13:30 - 13:45 Room Carl 1&2	Opening & Introduction Hans-Peter Hartung Xavier Montalban	Room Carl 1&2
13:45 - 14:15 Room Carl 1&2	34th ECF Comi-Hommes Lecture	Room Carl 1&2
14:15 - 15:45 Room Carl 1&2	Session I - Natural history: classic cohorts vs the modern era Hans-Peter Hartung Xavier Montalban	Room Carl 1&2
14:15 - 14:35	Changes in incidence and prevalence of MS over time Melinda Magyari
14:35 - 14:55	Learning about prognosis from cohorts initiated in the pre DMT era Sandra Vukusic
14:55 - 15:15	How early and high efficacy treatment has modified long-term prognosis Maria Trojano
15:15 - 15:35	Equity Matters: How Access to Diagnosis and Treatment Shapes MS Prognosis Ruth Dobson
15:35 - 15:45	Q&A
15:45 - 16:45	Coffee break & Poster viewing
16:45 - 18:15 Room Carl 1&2	Session II - Early diagnosis, early treatment, and long-term prognosis Alan Thompson Bernard M.J. Uitdehaag	Room Carl 1&2
16:45 - 17:05	The Will Rogers phenomenon in MS: the impact of different diagnostic criteria on MS prognosis Maria Pia Sormani
17:05 - 17:25	AI-Driven Classification: A New Lens on MS Prognosis Heinz Wiendl
17:25 - 17:45	MS Prognosis 2026: the PIRA and AI Era Carmen Tur
17:45 - 18:05	Overcoming Therapeutic Inertia: A Modifiable Determinant of Long-term MS Outcome Aksel Siva
18:05 - 18:15	Q&A
18:15 - 19:15 Room Carl 1&2	Satellite Symposium	Room Carl 1&2
19:15 - 20:00	Scientific Networking Cocktail

Hour Location	Title	Location
8:00-8:30 Room Carl 1&2	ACTRIMS Lecture: Challenges and opportunities regarding pediatric MS therapy Lauren Krupp	Room Carl 1&2
08:30 - 10:00 Room Carl 1&2	Session III - Pharmacovigilance in Practice: From Detection to Decision-Making Letizia Leocani Patrick Vermersch	Room Carl 1&2
08:30 - 08:50	Decoding Adverse Events Gabriel Bsteh
08:50 - 09:10	Safety Signals: From Reporting to Detection Across Clinical Care and Clinical Trials Sabine Straus
09:10 - 09:30	Risk Mitigation in Practice: A Practical Case Study Nico Melzer
09:30 - 09:50	Communicating Risk in MS Care Anne Helme
09:50 - 10:00	Q&A
10:00 - 10:30 Lobby & Winter Garden	Coffee Break & Poster Viewing	Lobby & Winter Garden
10:30 - 12:00 Room Carl 1&2	Session IV - Moderate- and High-Efficacy Therapies: Navigating the Known Risks Jefferson Becker Bernhard Hemmer	Room Carl 1&2
10:30 - 10:50	Injectables: Safety, Adherence, and Beyond Gilles Edan
10:50 - 11:10	Teriflunomide and Fumarates: The Long-Term Safety Profile Daniel Ontaneda
11:10 - 11:30	Cladribine: Long-Term Safety and Retreatment Per Soelberg Sørensen
11:30 - 11:50	S1P Modulators: Managing the Known Risks Krzysztof Selmaj
11:50 - 12:00	Q&A
12:00 - 13:00 Room Carl 1&2	Satellite Symposium	Room Carl 1&2
13:00 - 14:00 Lobby & Winter Garden	Light Lunch & Poster Viewing	Lobby & Winter Garden
14:00 - 15:30 Room Carl 1&2	Session V - High Reward, High Vigilance: Alemtuzumab, Natalizumab, and Anti-CD20 Therapies Fred Lublin Anne-Katrin Pröbstel	Room Carl 1&2
14:00 - 14:20	Alemtuzumab: The Long View on Safety Alasdair Coles
14:20 - 14:40	Natalizumab: Optimizing Efficacy, Minimizing PML Risk Eva Strijbis
14:40 - 15:00	Anti-CD20 Therapies: Long-Term Safety in Focus Fredrik Piehl
15:00 - 15:20	Anti-CD20 Therapies: When and How to De-escalate? Adil Maarouf
15:20 - 15:30	Q&A
15:30 - 17:00 Room Carl 1&2	Session VI - Emerging therapies Hans Lassmann Kjell-Morten Myhr	Room Carl 1&2
15:30 - 15:50	BTK Inhibitors: How Strong Is the Efficacy Signal? Jiwon Oh
15:50 - 16:10	BTK Inhibitors: Understanding the Safety Profile Xavier Montalban
16:10 - 16:30	CAR-T in MS and autoimmunity: From Concept to Clinic Manuel Friese
16:30 - 16:50	Beyond Anti-CD20: other monoclonal ab, antigen-specific tolerance and EBV-directed strategies Sven Meuth
16:50 - 17:00	Q&A
17:00 - 17:20 Lobby	Coffee Break	Lobby
17:20 - 18:20 Room Carl 1&2	Satellite Symposium	Room Carl 1&2
18:20 - 18:30 Room Carl 1&2	Announcement Young Investigator Award Winners	Room Carl 1&2
18:30 - 19:30 Room Carl 1&2	Satellite Symposium	Room Carl 1&2

Hour Location	Title	Location
8:30 - 10:00 Room Carl 1&2	Session VII - Lessons from neighbouring fields: what can MS learn from other immune-mediated and neurodegenerative diseases? Fu-Dong Shi Bassem Yamout	Room Carl 1&2
8:30 - 8:50	NMOSD and MOGAD: Long-Term Safety Lessons Jacqueline Palace
8:50 - 9:10	CIDP/GBS: long-term safety of current treatments Simon Rinaldi
9:10 - 9:30	Myasthenia Gravis: Managing Long-Term Treatment Risks Raffaele Iorio
9:30 - 9:50	Alzheimer’s disease: benefit–risk framing
9:50 - 10:00	Q&A
10:00 - 10:30 Lobby	Coffee break	Lobby
10:30 - 11:00 Room Carl 1&2	Young Investigator Awards - Announcement	Room Carl 1&2
11:00 - 12:30 Room Carl 1&2	Session VIII - Cross-Cutting Challenges in MS Treatment Ludwig Kappos Catherine Lubetzki	Room Carl 1&2
11:00 - 11:20	MS Across Life Stages: Pregnancy, Breastfeeding, and Vaccination Maria Pia Amato
11:20 - 11:40	Impact of generics and biosimilars Thomas Berger
11:40 - 12:00	Ageing with MS: Rethinking Treatment Decisions Benedetta Bodini
12:00 - 12:20	The Future of Benefit–Risk Assessment in MS Mark S. Freedman
12:20 - 12:30	Q&A
12:30 - 13:00 Room Carl 1&2	Concluding Remarks	Room Carl 1&2
13:00 - 14:00	Light Lunch